Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Investigational (phase 3) REDEFINE dataset with an FDA filing under review
In clinical conversations, MOTS-c is not treated as a shortcut
5 WARNINGS AND PRECAUTIONS WARNINGS AND PRECAUTIONS SECTION 6 ADVERSE REACTIONS ADVERSE REACTIONS SECTION The following serious adverse reactions are described below or elsewhere in the prescribing information: Risk of Thyroid C-cell Tumors [see Warnings and Precautions ( 5.1 )] Acute Pancreatitis [see Warnings and Precautions ( 5.2 )] Acute Gallbladder Disease [see Warnings and Precautions ( 5.3 )] Hypoglycemia [see Warnings and Precautions ( 5.4 )] Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions ( 5.5 )] Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions ( 5.6 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.7 )] Diabetic Retinopathy Complications in Patients with Type 2 Diabetes [see Warnings and Precautions ( 5.8 )] Heart Rate Increase [see Warnings and Precautions ( 5.9 )] Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions ( 5.10 )] 7 DRUG INTERACTIONS DRUG INTERACTIONS SECTION 8 USE IN SPECIFIC POPULATIONS USE IN SPECIFIC POPULATIONS SECTION 10 OVERDOSAGE OVERDOSAGE SECTION Overdoses have been reported with other GLP-1 receptor agonists
Patients sometimes skip therapy because of nausea, medication costs, supply shortages, or unrealistic expectations regarding results
